13 completed, 1 active not recruiting, 1 terminated. 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 13, Active not recruiting 1, Terminated 1 |
Follow Triapine: new trials by email Literature Review of Triapine trials Research Report on Triapine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Neuroendocrine Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2023-08-30 | 2026-07-31 |
| Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer triapine, cisplatin, external beam radiation therapy - Recurrent Cervical Cancer, Recurrent Vaginal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2009-07-01 | 2017-11-17 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia fludarabine phosphate, triapine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2006-08-01 | 2015-01-06 |
| 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer triapine, cisplatin, laboratory biomarker analysis - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2005-07-01 | 2013-01-24 |
| 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer triapine, gemcitabine hydrochloride, laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 68 | 2004-10-01 | 2013-01-16 |
| Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas triapine - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2004-07-01 | 2013-10-08 |
| A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer triapine, gemcitabine hydrochloride, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2004-07-01 | 2013-02-27 |
| 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma triapine - Kidney Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 19 | 2004-05-11 | 2023-08-04 |
| 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer gemcitabine hydrochloride, triapine - Pancreatic Cancer | Phase 2 | Completed | University Health Network, Toronto | 26 | 2004-04-01 | 2018-09-14 |
| 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer gemcitabine hydrochloride, triapine - Lung Cancer | Phase 2 | Completed | Cancer Therapeutics Research Group | 31 | 2004-04-01 | 2013-05-15 |
| 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction triapine, cisplatin - Adenocarcinoma of the Esophagus, Recurrent Esophageal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2004-01-01 | 2013-10-08 |
| Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer triapine, gemcitabine - Stage II Gallbladder Cancer, Stage IIIA Gallbladder Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 33 | 2003-11-01 | 2015-09-28 |
| 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer gemcitabine hydrochloride, triapine - Pancreatic Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 2003-01-01 | 2013-08-02 | |
| 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer gemcitabine hydrochloride, triapine - Lung Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 2003-01-01 | 2013-11-06 | |
| 3-AP in Treating Patients With Advanced Prostate Cancer triapine - Prostate Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 2002-12-01 | 2013-11-06 |
Carcinoma, Non-Small-Cell Lung (3) · Pancreatic Neoplasms (3) · Lung Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Blast Crisis (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Kidney Neoplasms (1) · Leukemia, Myeloid, Accelerated Phase (1)
National Cancer Institute (NCI) (9) · Vion Pharmaceuticals (3) · Cancer Therapeutics Research Group (1) · NCIC Clinical Trials Group (1) · University Health Network, Toronto (1)
United States (12) · Canada (2) · Australia (1) · Belgium (1) · Hong Kong (1) · Netherlands (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Mario Sznol, MD (3) · Allyson Ocean (1) · Ann Mauer (1) · Anne Traynor (1) · Brigette Ma, MD (1) · Charles Kunos (1) · James Stewart (1) · Jennifer Knox, MD (1) · Judith Karp (1) · Kyle Holen (1) · Lowell B Anthony (1) · Lydia Usha (1) · Malcolm J. Moore, MD (1)
PMID 17393073, PMID 20981545, PMID 22105720, PMID 22541066, PMID 24362550, PMID 36185311
N01CM62205 (2), N01CM62201 (1), N01CM62204 (1), P30CA006973 (1), P30CA043703 (1), U01CA062502 (1), U01CA062505 (1), U01CA070095 (1), U10CA021115 (1), U10CA027469 (1), UM1CA186712 (1)